Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

A drug library screen identifies Carbenoxolone as novel FOXO inhibitor that overcomes FOXO3-mediated chemoprotection in high-stage neuroblastoma.

Salcher S, Spoden G, Hagenbuchner J, Führer S, Kaserer T, Tollinger M, Huber-Cantonati P, Gruber T, Schuster D, Gust R, Zwierzina H, Müller T, Kiechl-Kohlendorfer U, Ausserlechner MJ, Obexer P.

Oncogene. 2019 Oct 7. doi: 10.1038/s41388-019-1044-7. [Epub ahead of print]

PMID:
31591479
2.

The Role of Mitochondria in the Mechanisms of Cardiac Ischemia-Reperfusion Injury.

Kuznetsov AV, Javadov S, Margreiter R, Grimm M, Hagenbuchner J, Ausserlechner MJ.

Antioxidants (Basel). 2019 Oct 6;8(10). pii: E454. doi: 10.3390/antiox8100454. Review.

3.

Forkhead Domains of FOXO Transcription Factors Differ in both Overall Conformation and Dynamics.

Psenakova K, Kohoutova K, Obsilova V, Ausserlechner MJ, Veverka V, Obsil T.

Cells. 2019 Aug 24;8(9). pii: E966. doi: 10.3390/cells8090966.

4.

Modulation of Respiration and Mitochondrial Dynamics by SMAC-Mimetics for Combination Therapy in Chemoresistant Cancer.

Hagenbuchner J, Oberacher H, Arnhard K, Kiechl-Kohlendorfer U, Ausserlechner MJ.

Theranostics. 2019 Jul 9;9(17):4909-4922. doi: 10.7150/thno.33758. eCollection 2019.

5.

Very long-/ and long Chain-3-Hydroxy Acyl CoA Dehydrogenase Deficiency correlates with deregulation of the mitochondrial fusion/fission machinery.

Hagenbuchner J, Scholl-Buergi S, Karall D, Ausserlechner MJ.

Sci Rep. 2018 Feb 19;8(1):3254. doi: 10.1038/s41598-018-21519-2.

6.

FOXO3-mediated chemo-protection in high-stage neuroblastoma depends on wild-type TP53 and SESN3.

Rupp M, Hagenbuchner J, Rass B, Fiegl H, Kiechl-Kohlendorfer U, Obexer P, Ausserlechner MJ.

Oncogene. 2017 Nov 2;36(44):6190-6203. doi: 10.1038/onc.2017.288. Epub 2017 Sep 4.

7.

C10ORF10/DEPP-mediated ROS accumulation is a critical modulator of FOXO3-induced autophagy.

Salcher S, Hermann M, Kiechl-Kohlendorfer U, Ausserlechner MJ, Obexer P.

Mol Cancer. 2017 May 25;16(1):95. doi: 10.1186/s12943-017-0661-4.

8.

Abstracts of the 52nd Workshop for Pediatric Research : Frankfurt, Germany. 27-28 October 2016.

van den Bruck R, Weil PP, Ziegenhals T, Schreiner P, Juranek S, Gödde D, Vogel S, Schuster F, Orth V, Dörner J, Pembaur D, Röper M, Störkel S, Zirngibl H, Wirth S, Jenke ACW, Postberg J, Boy N, Heringer J, Haege G, Glahn EM, Hoffmann GF, Garbade SF, Burgard P, Kölker S, Chao CM, Yahya F, Moiseenko A, Shrestha A, Ahmadvand N, Quantius J, Wilhelm J, El-Agha E, Zimmer KP, Bellusci S, Staufner C, Kölker S, Prokisch H, Hoffmann GF, Seeliger S, Müller M, Hippe A, Steinkraus H, Wauer R, Lachmann B, Hofmann SR, Hedrich CM, Zierk J, Arzideh F, Haeckel R, Rascher W, Rauh M, Metzler M, Thieme S, Bandoła J, Richter C, Ryser M, Jamal A, Ashton MP, von Bonin M, Kuhn M, Hedrich CM, Bonifacio E, Berner R, Brenner S, Hammersen J, Has C, Naumann-Bartsch N, Stachel D, Kiritsi D, Söder S, Tardieu M, Metzler M, Bruckner-Tuderman L, Schneider H, Bohne F, Langer D, Cencic R, Eggermann T, Zechner U, Pelletier J, Zepp F, Enklaar T, Prawitt D, Pech M, Weckmann M, Heinsen FA, Franke A, Happle C, Dittrich AM, Hansen G, Fuchs O, von Mutius E, Oliver BG, Kopp MV, Paret C, Russo A, Theruvath J, Keller B, El Malki K, Lehmann N, Wingerter A, Neu MA, Aslihan GA, Wagner W, Sommer C, Pietsch T, Seidmann L, Faber J, Schreiner F, Ackermann M, Michalik M, Rother E, Bilkei-Gorzo A, Racz I, Bindila L, Lutz B, Dötsch J, Zimmer A, Woelfle J, Fischer HS, Ullrich TL, Bührer C, Czernik C, Schmalisch G, Stein R, Hofmann SR, Hagenbuchner J, Kiechl-Kohlendorfer U, Obexer P, Ausserlechner MJ, Loges NT, Frommer AT, Wallmeier J, Omran H, Öner-Sieben S, Gimpfl M, Rozman J, Irmler M, Beckers J, De Angelis MH, Roscher A, Wolf E, Ensenauer R, Nemes K, Frühwald M, Hasselblatt M, Siebert R, Kordes U, Kool M, Wang H, Hardy H, Refai O, Barwick KES, Zimmerman HH, Weis J, Baple EL, Crosby AH, Cirak S, Hellmuth C, Uhl O, Standl M, Heinrich J, Thiering E, Koletzko B, Blümel L, Kerl K, Picard D, Frühwald MC, Liebau MC, Reifenberger G, Borkhardt A, Hasselblatt M, Remke M, Tews D, Wabitsch M, Fischer-Posovszky P, Westhoff MA, Nonnenmacher L, Langhans J, Schneele L, Trenkler N, Debatin KM.

Mol Cell Pediatr. 2017 May;4(Suppl 1):5. doi: 10.1186/s40348-017-0071-0. No abstract available.

9.

The tubulin inhibitor MG-2477 induces autophagy-regulated cell death, ROS accumulation and activation of FOXO3 in neuroblastoma.

Hagenbuchner J, Lungkofler L, Kiechl-Kohlendorfer U, Viola G, Ferlin MG, Ausserlechner MJ, Obexer P.

Oncotarget. 2017 May 9;8(19):32009-32026. doi: 10.18632/oncotarget.16434.

10.

Nuclear FOXO3 predicts adverse clinical outcome and promotes tumor angiogenesis in neuroblastoma.

Hagenbuchner J, Rupp M, Salvador C, Meister B, Kiechl-Kohlendorfer U, Müller T, Geiger K, Sergi C, Obexer P, Ausserlechner MJ.

Oncotarget. 2016 Nov 22;7(47):77591-77606. doi: 10.18632/oncotarget.12728.

11.

Mitochondrial survivin - an Achilles' heel in cancer chemoresistance.

Ausserlechner MJ, Hagenbuchner J.

Mol Cell Oncol. 2015 Jul 29;3(2):e1076589. doi: 10.1080/23723556.2015.1076589. eCollection 2016 Mar.

12.

Characterization of the XIAP-Inhibiting Proanthocyanidin Fraction of the Aerial Parts of Ephedra sinica.

Schäfer S, Salcher S, Seiter M, Ranninger C, Möst M, Obexer P, Huber CG, Ausserlechner MJ, Schwaiger S, Stuppner H.

Planta Med. 2016 Jul;82(11-12):973-85. doi: 10.1055/s-0042-107253. Epub 2016 May 24.

PMID:
27220077
13.

Targeting transcription factors by small compounds--Current strategies and future implications.

Hagenbuchner J, Ausserlechner MJ.

Biochem Pharmacol. 2016 May 1;107:1-13. doi: 10.1016/j.bcp.2015.12.006. Epub 2015 Dec 11. Review.

PMID:
26686579
14.

BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma.

Hagenbuchner J, Kiechl-Kohlendorfer U, Obexer P, Ausserlechner MJ.

Oncogene. 2016 Apr 21;35(16):2052-61. doi: 10.1038/onc.2015.264. Epub 2015 Jul 6.

PMID:
26148234
15.

C10ORF10/DEPP, a transcriptional target of FOXO3, regulates ROS-sensitivity in human neuroblastoma.

Salcher S, Hagenbuchner J, Geiger K, Seiter MA, Rainer J, Kofler R, Hermann M, Kiechl-Kohlendorfer U, Ausserlechner MJ, Obexer P.

Mol Cancer. 2014 Sep 28;13:224. doi: 10.1186/1476-4598-13-224.

16.

Discovery of Sanggenon G as a natural cell-permeable small-molecular weight inhibitor of X-linked inhibitor of apoptosis protein (XIAP).

Seiter MA, Salcher S, Rupp M, Hagenbuchner J, Kiechl-Kohlendorfer U, Mortier J, Wolber G, Rollinger JM, Obexer P, Ausserlechner MJ.

FEBS Open Bio. 2014 Jul 5;4:659-71. doi: 10.1016/j.fob.2014.07.001. eCollection 2014.

17.

X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy.

Obexer P, Ausserlechner MJ.

Front Oncol. 2014 Jul 28;4:197. doi: 10.3389/fonc.2014.00197. eCollection 2014. Review.

18.

A novel Mcl1 variant inhibits apoptosis via increased Bim sequestration.

Hagenbuchner J, Kiechl-Kohlendorfer U, Obexer P, Ausserlechner MJ.

Oncotarget. 2013 Aug;4(8):1241-52.

19.

Therapy-resistant acute lymphoblastic leukemia (ALL) cells inactivate FOXO3 to escape apoptosis induction by TRAIL and Noxa.

Ausserlechner MJ, Salvador C, Deutschmann A, Bodner M, Viola G, Bortolozzi R, Basso G, Hagenbuchner J, Obexer P.

Oncotarget. 2013 Jul;4(7):995-1007.

20.

Mitochondria and FOXO3: breath or die.

Hagenbuchner J, Ausserlechner MJ.

Front Physiol. 2013 Jun 20;4:147. doi: 10.3389/fphys.2013.00147. eCollection 2013.

21.

BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery.

Hagenbuchner J, Kuznetsov AV, Obexer P, Ausserlechner MJ.

Oncogene. 2013 Oct;32(40):4748-57. doi: 10.1038/onc.2012.500. Epub 2012 Nov 12.

PMID:
23146905
22.

FOXO3/FKHRL1 is activated by 5-aza-2-deoxycytidine and induces silenced caspase-8 in neuroblastoma.

Geiger K, Hagenbuchner J, Rupp M, Fiegl H, Sergi C, Meister B, Kiechl-Kohlendorfer U, Müller T, Ausserlechner MJ, Obexer P.

Mol Biol Cell. 2012 Jun;23(11):2226-34. doi: 10.1091/mbc.E11-06-0535. Epub 2012 Apr 4.

23.

FOXO3-induced reactive oxygen species are regulated by BCL2L11 (Bim) and SESN3.

Hagenbuchner J, Kuznetsov A, Hermann M, Hausott B, Obexer P, Ausserlechner MJ.

J Cell Sci. 2012 Mar 1;125(Pt 5):1191-203. doi: 10.1242/jcs.092098. Epub 2012 Feb 20.

24.

The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression.

Hagenbuchner J, Ausserlechner MJ, Porto V, David R, Meister B, Bodner M, Villunger A, Geiger K, Obexer P.

J Biol Chem. 2010 Mar 5;285(10):6904-12. doi: 10.1074/jbc.M109.038331. Epub 2010 Jan 5.

25.

The cell senescence inducing gene product MORF4 is regulated by degradation via the ubiquitin/proteasome pathway.

Tominaga K, Tominaga E, Ausserlechner MJ, Pereira-Smith OM.

Exp Cell Res. 2010 Jan 1;316(1):92-102. doi: 10.1016/j.yexcr.2009.09.015. Epub 2009 Sep 19.

26.

p16INK4A sensitizes human leukemia cells to FAS- and glucocorticoid-induced apoptosis via induction of BBC3/Puma and repression of MCL1 and BCL2.

Obexer P, Hagenbuchner J, Rupp M, Salvador C, Holzner M, Deutsch M, Porto V, Kofler R, Unterkircher T, Ausserlechner MJ.

J Biol Chem. 2009 Nov 6;284(45):30933-40. doi: 10.1074/jbc.M109.051441. Epub 2009 Sep 8.

27.

Premature aging of the immune system in children with juvenile idiopathic arthritis.

Prelog M, Schwarzenbrunner N, Sailer-Höck M, Kern H, Klein-Franke A, Ausserlechner MJ, Koppelstaetter C, Brunner A, Duftner C, Dejaco C, Strasak AM, Müller T, Zimmerhackl LB, Brunner J.

Arthritis Rheum. 2008 Jul;58(7):2153-62. doi: 10.1002/art.23599.

28.

Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation.

Spoden GA, Mazurek S, Morandell D, Bacher N, Ausserlechner MJ, Jansen-Dürr P, Eigenbrodt E, Zwerschke W.

Int J Cancer. 2008 Jul 15;123(2):312-321. doi: 10.1002/ijc.23512.

29.
30.

FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells.

Obexer P, Geiger K, Ambros PF, Meister B, Ausserlechner MJ.

Cell Death Differ. 2007 Mar;14(3):534-47. Epub 2006 Aug 4.

31.

Successful transplantation in a child with rapid progression of autosomal recessive polycystic kidney disease associated with a novel mutation.

Prelog M, Bergmann C, Ausserlechner MJ, Fischer H, Margreiter R, Gassner I, Brunner A, Jungraithmayr TC, Zerres K, Sergi C, Zimmerhackl LB.

Pediatr Transplant. 2006 May;10(3):362-6. Erratum in: Pediatr Transplant. 2008 Mar;12(2):256. Sergi, E Consolato [corrected to Sergi, Consolato].

PMID:
16677362
32.

Oxindole alkaloids from Uncaria tomentosa induce apoptosis in proliferating, G0/G1-arrested and bcl-2-expressing acute lymphoblastic leukaemia cells.

Bacher N, Tiefenthaler M, Sturm S, Stuppner H, Ausserlechner MJ, Kofler R, Konwalinka G.

Br J Haematol. 2006 Mar;132(5):615-22.

PMID:
16445836
33.
34.
35.

Functional analysis of the mutated Epstein-Barr virus oncoprotein LMP1(69del): implications for a new role of naturally occurring LMP1 variants.

Larcher C, Bernhard D, Schaadt E, Adler B, Ausserlechner MJ, Mitterer M, Huemer HP.

Haematologica. 2003 Dec;88(12):1324-35.

36.
37.

Cyclin D3 and c-MYC control glucocorticoid-induced cell cycle arrest but not apoptosis in lymphoblastic leukemia cells.

Ausserlechner MJ, Obexer P, Böck G, Geley S, Kofler R.

Cell Death Differ. 2004 Feb;11(2):165-74.

38.

p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa.

Villunger A, Michalak EM, Coultas L, Müllauer F, Böck G, Ausserlechner MJ, Adams JM, Strasser A.

Science. 2003 Nov 7;302(5647):1036-8. Epub 2003 Sep 18.

39.

Resistance to glucocorticoid-induced apoptosis in lymphoblastic leukemia.

Kofler R, Schmidt S, Kofler A, Ausserlechner MJ.

J Endocrinol. 2003 Jul;178(1):19-27. Review.

PMID:
12844332
40.

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species.

Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, Johnstone RW.

Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10833-8. Epub 2001 Sep 4.

41.

The cell cycle inhibitor p16(INK4A) sensitizes lymphoblastic leukemia cells to apoptosis by physiologic glucocorticoid levels.

Ausserlechner MJ, Obexer P, Wiegers GJ, Hartmann BL, Geley S, Kofler R.

J Biol Chem. 2001 Jun 15;276(24):10984-9.

42.

The cell cycle inhibitor p16(INK4A) sensitizes lymphoblastic leukemia cells to apoptosis by physiologic glucocorticoid levels.

Ausserlechner MJ, Obexer P, Wiegers GJ, Hartmann BL, Geley S, Kofler R.

J Biol Chem. 2001 Apr 6;276(14):10984-9. Epub 2001 Jan 12. Corrected and republished in: J Biol Chem. 2001 Jun 15;276(24):10984-9.

43.

Gene expression profiles of proliferating vs. G1/G0 arrested human leukemia cells suggest a mechanism for glucocorticoid-induced apoptosis.

Tonko M, Ausserlechner MJ, Bernhard D, Helmberg A, Kofler R.

FASEB J. 2001 Mar;15(3):693-9.

PMID:
11259387
44.

Resveratrol causes arrest in the S-phase prior to Fas-independent apoptosis in CEM-C7H2 acute leukemia cells.

Bernhard D, Tinhofer I, Tonko M, Hübl H, Ausserlechner MJ, Greil R, Kofler R, Csordas A.

Cell Death Differ. 2000 Sep;7(9):834-42.

45.

Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts.

Bernhard D, Ausserlechner MJ, Tonko M, Löffler M, Hartmann BL, Csordas A, Kofler R.

FASEB J. 1999 Nov;13(14):1991-2001.

PMID:
10544182
46.

c-Myc does not prevent glucocorticoid-induced apoptosis of human leukemic lymphoblasts.

Löffler M, Ausserlechner MJ, Tonko M, Hartmann BL, Bernhard D, Geley S, Helmberg A, Kofler R.

Oncogene. 1999 Aug 12;18(32):4626-31.

47.

Chemiluminescence-based RNase protection assays for simultaneous quantification of procollagen mRNAs containing AU-rich regions.

Ausserlechner MJ, Sgonc R, Wick G.

Biotechniques. 1998 Mar;24(3):366-8, 370. No abstract available.

48.

p53-induced apoptosis in the human T-ALL cell line CCRF-CEM.

Geley S, Hartmann BL, Hattmannstorfer R, Löffler M, Ausserlechner MJ, Bernhard D, Sgonc R, Strasser-Wozak EM, Ebner M, Auer B, Kofler R.

Oncogene. 1997 Nov 13;15(20):2429-37.

49.

Altered procollagen mRNA expression during the progression of avian scleroderma.

Ausserlechner MJ, Sgonc R, Dietrich H, Wick G.

Mol Med. 1997 Oct;3(10):654-62.

Supplemental Content

Loading ...
Support Center